[A17-49] Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2018
Project no.:
A17-49
Commission:
Commission awarded on 28.09.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Indication:
Adult patients with moderate to severe psoriasis vulgaris who require systemic drug therapy
Result of dossier assessment:
No added benefit proven because of a lack of suitable study data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-14 | Dimethyl fumarate - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |